Cholecalciferol (VD3) Attenuates L-DOPA-Induced Dyskinesia in Parkinsonian Mice Via Modulation of Microglia and Oxido-Inflammatory Mechanisms.

Q4 Medicine
Adedamola Bayo-Olugbami, AbdulRazaq Bidemi Nafiu, Abdulbasit Amin, Olalekan Michael Ogundele, Charles C Lee, Bamidele Victor Owoyele
{"title":"Cholecalciferol (VD3) Attenuates L-DOPA-Induced Dyskinesia in Parkinsonian Mice Via Modulation of Microglia and Oxido-Inflammatory Mechanisms.","authors":"Adedamola Bayo-Olugbami, AbdulRazaq Bidemi Nafiu, Abdulbasit Amin, Olalekan Michael Ogundele, Charles C Lee, Bamidele Victor Owoyele","doi":"10.54548/njps.v37i2.3","DOIUrl":null,"url":null,"abstract":"<p><p>L-DOPA, the gold standard for managing Parkinson's disease (PD) is fraught by motor fluctuations termed L-Dopa-Induced Dyskinesia (LID). LID has very few therapeutic options. Hence, the need for preclinical screening of new interventions. Cholecalciferol (VD3) treatment reportedly improves motor deficit in experimental Parkinsonism. Therefore, the novel anti-dyskinetic effect of VD3 and its underlying mechanisms in LID was investigated. Dyskinesia was induced by chronic L-DOPA administration in parkinsonian (6-OHDA- lesioned) mice. The experimental groups: Control, Dyskinesia, Dyskinesia/VD3, and Dyskinesia/Amantadine were challenged with L-DOPA to determine the abnormal involuntary movements (AIMs) score during 14 days of VD3 (30 mg/kg) or Amantadine (40 mg/kg) treatment. Behavioral Axial, Limb & Orolingual (ALO) AIMs were scored for 1 min at every 20 mins interval, over a duration of 100 mins on days 1,3,7,11 and 14. Using western blot, striatum was assessed for expression of dopamine metabolic enzymes: Tyrosine Hydroxylase (TH) and Monoamine Oxidase-B (MAO-B); CD11b, BAX, P47phox, and IL-1β. Cholecalciferol significantly attenuated AIMs only on days 11 & 14 with maximal reduction of 32.7%. Expression of TH and MAO-B was not altered in VD3 compared with dyskinetic mice. VD3 significantly inhibited oxidative stress (P47phox), apoptosis (BAX), inflammation (IL-1β) and microglial activation (CD11b). VD3 showed anti-dyskinetic effects behaviorally by attenuating abnormal involuntary movements, modulation of striatal oxidative stress, microglial responses, inflammation, and apoptotic signaling; without affecting dopamine metabolic enzymes. Its use in the management of dyskinesia is promising. More studies are required to further evaluate these findings. Keywords: Cholecalciferol; L-DOPA-Induced Dyskinesia; Parkinson's Disease; Microglial; Oxidative stress; Inflammation.</p>","PeriodicalId":35043,"journal":{"name":"Nigerian Journal of Physiological Sciences","volume":" ","pages":"175-183"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10800002/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nigerian Journal of Physiological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54548/njps.v37i2.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

L-DOPA, the gold standard for managing Parkinson's disease (PD) is fraught by motor fluctuations termed L-Dopa-Induced Dyskinesia (LID). LID has very few therapeutic options. Hence, the need for preclinical screening of new interventions. Cholecalciferol (VD3) treatment reportedly improves motor deficit in experimental Parkinsonism. Therefore, the novel anti-dyskinetic effect of VD3 and its underlying mechanisms in LID was investigated. Dyskinesia was induced by chronic L-DOPA administration in parkinsonian (6-OHDA- lesioned) mice. The experimental groups: Control, Dyskinesia, Dyskinesia/VD3, and Dyskinesia/Amantadine were challenged with L-DOPA to determine the abnormal involuntary movements (AIMs) score during 14 days of VD3 (30 mg/kg) or Amantadine (40 mg/kg) treatment. Behavioral Axial, Limb & Orolingual (ALO) AIMs were scored for 1 min at every 20 mins interval, over a duration of 100 mins on days 1,3,7,11 and 14. Using western blot, striatum was assessed for expression of dopamine metabolic enzymes: Tyrosine Hydroxylase (TH) and Monoamine Oxidase-B (MAO-B); CD11b, BAX, P47phox, and IL-1β. Cholecalciferol significantly attenuated AIMs only on days 11 & 14 with maximal reduction of 32.7%. Expression of TH and MAO-B was not altered in VD3 compared with dyskinetic mice. VD3 significantly inhibited oxidative stress (P47phox), apoptosis (BAX), inflammation (IL-1β) and microglial activation (CD11b). VD3 showed anti-dyskinetic effects behaviorally by attenuating abnormal involuntary movements, modulation of striatal oxidative stress, microglial responses, inflammation, and apoptotic signaling; without affecting dopamine metabolic enzymes. Its use in the management of dyskinesia is promising. More studies are required to further evaluate these findings. Keywords: Cholecalciferol; L-DOPA-Induced Dyskinesia; Parkinson's Disease; Microglial; Oxidative stress; Inflammation.

胆钙化醇(VD3)通过调节小胶质细胞和氧化应激炎症机制减轻帕金森病小鼠中左旋多巴诱导的运动障碍。
作为治疗帕金森病(PD)的金标准,左旋多巴充满了被称为左旋多巴诱导的运动障碍(LID)的运动波动。LID的治疗选择很少。因此,需要对新的干预措施进行临床前筛查。据报道,胆钙化醇(VD3)治疗可改善实验性帕金森病的运动缺陷。因此,研究了VD3的新型抗动力学障碍作用及其在LID中的潜在机制。帕金森病(6-OHDA损伤)小鼠通过长期服用左旋多巴诱发运动障碍。实验组:对照组、运动障碍组、运动功能障碍/VD3组和运动障碍/金刚烷胺组在VD3(30 mg/kg)或金刚烷胺(40 mg/kg)治疗的14天内用L-DOPA激发,以确定异常非自主运动(AIMs)评分。在第1、3、7、11和14天的100分钟内,每隔20分钟对行为轴位、肢体和口舌(ALO)AIMs进行1分钟的评分。使用蛋白质印迹法,评估纹状体多巴胺代谢酶的表达:酪氨酸羟化酶(TH)和单胺氧化酶-B(MAO-B);CD11b、BAX、P47phox和IL-1β。胆钙化醇仅在第11和14天显著减弱AIMs,最大减少32.7%。与运动障碍小鼠相比,VD3中TH和MAO-B的表达没有改变。VD3显著抑制氧化应激(P47phox)、细胞凋亡(BAX)、炎症(IL-1β)和小胶质细胞活化(CD11b)。VD3通过减弱异常的不自主运动、纹状体氧化应激的调节、小胶质细胞反应、炎症和凋亡信号传导,在行为上表现出抗运动障碍作用;而不影响多巴胺代谢酶。它在运动障碍治疗中的应用前景广阔。需要更多的研究来进一步评估这些发现。关键词:胆钙化醇;左旋多巴诱导的运动障碍;帕金森病;微胶质细胞;氧化应激;发炎
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nigerian Journal of Physiological Sciences
Nigerian Journal of Physiological Sciences Medicine-Physiology (medical)
CiteScore
0.80
自引率
0.00%
发文量
23
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信